|
US5080898A
(en)
|
1982-05-12 |
1992-01-14 |
The University Hospital |
Enzymatically active toxin coupled to a cell-specific ligand
|
|
US5668255A
(en)
|
1984-06-07 |
1997-09-16 |
Seragen, Inc. |
Hybrid molecules having translocation region and cell-binding region
|
|
US6022950A
(en)
|
1984-06-07 |
2000-02-08 |
Seragen, Inc. |
Hybrid molecules having translocation region and cell-binding region
|
|
US5091178A
(en)
|
1986-02-21 |
1992-02-25 |
Oncogen |
Tumor therapy with biologically active anti-tumor antibodies
|
|
US7838216B1
(en)
|
1986-03-05 |
2010-11-23 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Human gene related to but distinct from EGF receptor gene
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
US5135736A
(en)
|
1988-08-15 |
1992-08-04 |
Neorx Corporation |
Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
|
|
EP0474727B1
(en)
|
1989-05-19 |
1997-07-23 |
Genentech, Inc. |
Her2 extracellular domain
|
|
AU657087B2
(en)
|
1989-12-22 |
1995-03-02 |
Seragen Incorporated |
Hybrid molecules having translocation region and cell-binding region
|
|
US5578482A
(en)
|
1990-05-25 |
1996-11-26 |
Georgetown University |
Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
|
|
US5635384A
(en)
|
1990-06-11 |
1997-06-03 |
Dowelanco |
Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
|
|
IL101943A0
(en)
|
1991-05-24 |
1992-12-30 |
Genentech Inc |
Structure,production and use of heregulin
|
|
US5834229A
(en)
|
1991-05-24 |
1998-11-10 |
Genentech, Inc. |
Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US5621083A
(en)
|
1991-11-04 |
1997-04-15 |
Xoma Corporation |
Immunotoxins comprising ribosome-inactivating proteins
|
|
US6146850A
(en)
|
1991-11-04 |
2000-11-14 |
Xoma Corporation |
Proteins encoding gelonin sequences
|
|
AU4025193A
(en)
|
1992-04-08 |
1993-11-18 |
Cetus Oncology Corporation |
Humanized C-erbB-2 specific antibodies
|
|
JPH08504172A
(ja)
|
1992-06-30 |
1996-05-07 |
オンコロジクス，インコーポレイティド |
抗−ｅｒｂＢ−２モノクロナール抗体の組み合わせ物及び使用方法
|
|
FR2697695B1
(fr)
|
1992-11-04 |
1995-01-13 |
Cachan Ecole Normale Superieur |
Dispositif de conversion électromécanique produisant un mouvement en particulier linéaire.
|
|
US5869445A
(en)
|
1993-03-17 |
1999-02-09 |
University Of Washington |
Methods for eliciting or enhancing reactivity to HER-2/neu protein
|
|
AU6912294A
(en)
|
1993-05-12 |
1994-12-12 |
Xoma Corporation |
Immunotoxins comprising ribosome-inactivating proteins
|
|
CA2218601A1
(en)
|
1995-03-24 |
1996-10-03 |
Ophidian Pharmaceuticals, Inc. |
Treatment for verotoxin-producing escherichia coli
|
|
US5667786A
(en)
|
1995-06-07 |
1997-09-16 |
Novavax, Inc. |
Method for treating tumors with a toxin
|
|
WO1997000271A1
(en)
|
1995-06-14 |
1997-01-03 |
The Regents Of The University Of California |
Novel high affinity human antibodies to tumor antigens
|
|
US5783186A
(en)
|
1995-12-05 |
1998-07-21 |
Amgen Inc. |
Antibody-induced apoptosis
|
|
US5858682A
(en)
|
1996-08-02 |
1999-01-12 |
Pharmingen |
E2A/pbx1 fusion protein specific monoclonal antibodies
|
|
WO1998007797A1
(en)
|
1996-08-22 |
1998-02-26 |
Kaneka Corporation |
Curable composition for top coating and articles coated using the same
|
|
CZ295838B6
(cs)
|
1996-09-09 |
2005-11-16 |
Zealand Pharma A/S |
Způsob výroby peptidů
|
|
CA2265887A1
(en)
|
1996-09-10 |
1998-03-19 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
|
|
US5770380A
(en)
|
1996-09-13 |
1998-06-23 |
University Of Pittsburgh |
Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold
|
|
US6306393B1
(en)
|
1997-03-24 |
2001-10-23 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
FR2766193B1
(fr)
|
1997-07-18 |
2001-09-14 |
Inst Curie |
Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
|
|
CA2222993A1
(en)
|
1998-02-04 |
1999-08-04 |
The Ontario Cancer Institute |
A method for using a ribosome-inactivating protein complex as a structural template and a molecular search engine in the design, construction and screening of combinatorial protein libraries
|
|
AU770718B2
(en)
|
1998-06-05 |
2004-02-26 |
Mayo Foundation For Medical Education And Research |
Use of genetically engineered antibodies to CD38 to treat multiple myeloma
|
|
WO2000004926A2
(en)
|
1998-07-22 |
2000-02-03 |
Osprey Pharmaceuticals Limited |
Conjugates for treating inflammatory disorders and associated tissue damage
|
|
US7157418B1
(en)
|
1998-07-22 |
2007-01-02 |
Osprey Pharmaceuticals, Ltd. |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
|
US6770456B1
(en)
|
1998-07-29 |
2004-08-03 |
Ludwig Institute For Cancer Research |
Endogenous retrovirus tumor associated nucleic acids and antigens
|
|
WO2000020579A1
(en)
|
1998-10-02 |
2000-04-13 |
Mcmaster University |
Spliced form of erbb-2/neu oncogene
|
|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
US7144991B2
(en)
|
1999-06-07 |
2006-12-05 |
Aletheon Pharmaceuticals, Inc. |
Streptavidin expressed gene fusions and methods of use thereof
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
EP1189931B1
(en)
|
1999-07-02 |
2006-06-21 |
Genentech, Inc. |
Peptide compounds that bind her2
|
|
US6492498B1
(en)
|
1999-11-15 |
2002-12-10 |
Regents Of The University Of Minnesota |
Multimeric immunotoxins
|
|
US20010031485A1
(en)
|
2000-03-22 |
2001-10-18 |
Sibtech, Inc. |
Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
|
|
US7267973B2
(en)
|
2000-03-22 |
2007-09-11 |
Sibtech, Inc. |
Nucleic acids encoding recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor
|
|
PT2857516T
(pt)
|
2000-04-11 |
2017-08-28 |
Genentech Inc |
Anticorpos multivalentes e utilizações dos mesmos
|
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
US7446185B2
(en)
|
2001-07-18 |
2008-11-04 |
The Regents Of The University Of California |
Her2/neu target antigen and use of same to stimulate an immune response
|
|
WO2003066854A1
(fr)
|
2002-02-04 |
2003-08-14 |
Yoshida, Hideo |
Agent anticancereux utilisant des variantes de verotoxines
|
|
US20040248151A1
(en)
|
2002-04-05 |
2004-12-09 |
Ventana Medical Systems, Inc. |
Method for predicting the response to HER2-directed therapy
|
|
JP2005522514A
(ja)
|
2002-04-10 |
2005-07-28 |
ジェネンテック・インコーポレーテッド |
抗ｈｅｒ２抗体改変体
|
|
US7449480B2
(en)
|
2002-05-14 |
2008-11-11 |
Baylor College Of Medicine |
Small molecule inhibitors of HER2 expression
|
|
AU2003237790A1
(en)
|
2002-05-14 |
2003-12-02 |
Baylor College Of Medicine |
Small molecule inhibitors of her2 expression
|
|
HUE035898T2
(en)
|
2002-12-16 |
2018-05-28 |
Genentech Inc |
Immunoglobulin variants and their applications
|
|
WO2004058158A2
(en)
|
2002-12-20 |
2004-07-15 |
The Johns Hopkins University |
Treatment of metastatic cancer with the b-subunit of shiga toxin
|
|
AU2003294023B2
(en)
|
2003-01-03 |
2008-01-31 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Rhesus HER2/neu, nucleotides encoding same, and uses thereof
|
|
US7834258B2
(en)
|
2003-06-30 |
2010-11-16 |
Mu-Hyeon Choe |
Dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
|
|
CA2531238C
(en)
|
2003-07-04 |
2015-02-24 |
Affibody Ab |
Polypeptides having binding affinity for her2
|
|
EP1660010B1
(en)
|
2003-08-01 |
2013-07-24 |
A & G Pharmaceutical, Inc. |
Compositions and methods for restoring sensitivity to treatment with her2 antagonists
|
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
|
DE602004027291D1
(de)
|
2003-11-25 |
2010-07-01 |
Us Gov Health & Human Serv |
Mutierte anti-cd22-antikörper und immunkonjugate
|
|
US7585942B2
(en)
|
2003-11-25 |
2009-09-08 |
Anjin Corporation |
Diphtheria toxin variant
|
|
ATE467641T1
(de)
|
2004-03-26 |
2010-05-15 |
Molecular Templates Inc |
Bibliothek von toxin mutanten und deren verwendung
|
|
UA90480C2
(uk)
|
2004-07-22 |
2010-05-11 |
Джэнэнтэк, Инк. |
Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2
|
|
EP2551282A3
(en)
|
2005-03-23 |
2013-02-13 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
|
US7771955B2
(en)
|
2005-06-09 |
2010-08-10 |
University Of Maryland |
Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
FI20055417A0
(fi)
|
2005-07-20 |
2005-07-20 |
Glykos Finland Oy |
Syöpäpesifiset glykaanit ja niiden käyttö
|
|
WO2007014238A2
(en)
|
2005-07-25 |
2007-02-01 |
Trubion Pharmaceuticals, Inc. |
Single dose use of cd20-specific binding molecules
|
|
CA2664549A1
(en)
|
2005-09-26 |
2007-03-29 |
University Health Network |
Library from toxin mutants, and methods of using same
|
|
WO2007071061A1
(en)
|
2005-12-23 |
2007-06-28 |
Viventia Biotech Inc. |
Methods for generating and screening fusion protein libraries and uses thereof
|
|
EP1991565B1
(en)
|
2006-02-16 |
2015-01-21 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Shiga toxoid chimeric proteins
|
|
JP4954293B2
(ja)
|
2006-12-29 |
2012-06-13 |
オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド |
改変毒素を選択および生産する方法、改変毒素を含む複合体、およびそれらの使用
|
|
ES2798758T3
(es)
|
2007-06-06 |
2020-12-14 |
Sarepta Therapeutics Inc |
Proteínas variantes de empalme her2 y her3 solubles, oligonucleótidos de cambio de empalme y su uso en el tratamiento de enfermedades
|
|
US20090010966A1
(en)
|
2007-06-21 |
2009-01-08 |
Angelica Therapeutics, Inc. |
Modified diphtheria toxins
|
|
US7887801B2
(en)
|
2007-07-13 |
2011-02-15 |
Topotarget Germany Ag |
Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
|
|
US9364557B2
(en)
|
2007-08-01 |
2016-06-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fold-back diabody diphtheria toxin immunotoxin and methods of use
|
|
DK2197903T3
(en)
|
2007-09-04 |
2015-01-05 |
Us Gov Health & Human Serv |
Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY
|
|
US20100298238A1
(en)
|
2007-10-08 |
2010-11-25 |
Rutgers, The State University |
Nontoxic shiga-like toxin mutant compositions and methods
|
|
US20090148904A1
(en)
|
2007-11-13 |
2009-06-11 |
Mayfield Stephen P |
Production of cytotoxic antibody-toxin fusion in eukaryotic algae
|
|
CA2706425A1
(en)
|
2007-11-27 |
2009-06-04 |
Ablynx N.V. |
Method for obtaining polypeptide constructs comprising two or more single domain antibodies
|
|
WO2009078766A1
(en)
|
2007-12-17 |
2009-06-25 |
Telefonaktiebolaget Lm Ericsson (Publ) |
Multi-antenna receiver interference cancellation method and apparatus
|
|
EP2072525A1
(en)
|
2007-12-21 |
2009-06-24 |
Affibody AB |
New polypeptides having affinity for HER2
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
EP2268297A4
(en)
|
2008-02-29 |
2011-11-16 |
Angelica Therapeutics Inc |
MODIFIED TOXINS
|
|
ES2342646B1
(es)
|
2008-06-02 |
2011-04-26 |
Institut De Recerca Hospital Universitari Vall Hebron |
Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas.
|
|
CN102159243B
(zh)
|
2008-07-21 |
2015-08-19 |
免疫医疗公司 |
用于改良的治疗特征的抗体的结构变体
|
|
US20110280913A1
(en)
|
2008-07-31 |
2011-11-17 |
The Ohio State University |
Methods and Compositions for Delivering Therapeutic Agents in the Treatment of B-Cell Related Disorders
|
|
AU2009293640A1
(en)
|
2008-09-22 |
2010-03-25 |
Calmune Corporation |
Methods and vectors for display of 2G12 -derived domain exchanged antibodies
|
|
US8969529B2
(en)
|
2009-01-23 |
2015-03-03 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Methods and compositions based on shiga toxin type 2 protein
|
|
US9034341B2
(en)
|
2009-04-20 |
2015-05-19 |
Transtech Pharma, Llc |
Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
|
|
EP2456470A1
(en)
|
2009-07-22 |
2012-05-30 |
Cenix Bioscience GmbH |
Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
|
|
US9174169B2
(en)
|
2009-08-14 |
2015-11-03 |
Unifrax I Llc |
Mounting mat for exhaust gas treatment device
|
|
EP2371864A1
(en)
|
2010-03-23 |
2011-10-05 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
|
KR20130108069A
(ko)
|
2010-04-15 |
2013-10-02 |
알퍼 바이오테크, 엘엘씨 |
Ｈｅｒ2 항원에 대한 모노클로날 항체 및 그를 위한 용도
|
|
IL299365A
(en)
|
2010-05-27 |
2023-02-01 |
Genmab As |
Monoclonal antibodies against 2HER
|
|
GB201013989D0
(en)
|
2010-08-20 |
2010-10-06 |
Univ Southampton |
Biological materials and methods of using the same
|
|
PL219845B1
(pl)
|
2011-01-05 |
2015-07-31 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Przeciwnowotworowe białko fuzyjne
|
|
WO2012101235A1
(en)
|
2011-01-26 |
2012-08-02 |
Cenix Bioscience Gmbh |
Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
|
|
SG191977A1
(en)
|
2011-02-01 |
2013-08-30 |
Genmab As |
Human antibodies and antibody-drug conjugates against cd74
|
|
US8895006B2
(en)
|
2011-03-04 |
2014-11-25 |
Rutgers, The State University Of New Jersey |
Ricin ribosome binding protein compositions and methods of use thereof
|
|
EP2704739B1
(en)
|
2011-05-06 |
2017-07-12 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
Recombinant immunotoxin targeting mesothelin
|
|
PL397167A1
(pl)
|
2011-11-28 |
2013-06-10 |
Adamed Spólka Z Ograniczona Odpowiedzialnoscia |
Przeciwnowotworowe bialko fuzyjne
|
|
CA2865243A1
(en)
|
2012-02-23 |
2013-08-29 |
President And Fellows Of Harvard College |
Modified microbial toxin receptor for delivering agents into cells
|
|
CN111363047A
(zh)
|
2013-03-12 |
2020-07-03 |
分子模板公司 |
用于引起细胞内化的cd20结合免疫毒素及其使用方法
|
|
GB2519786A
(en)
|
2013-10-30 |
2015-05-06 |
Sergej Michailovic Kiprijanov |
Multivalent antigen-binding protein molecules
|
|
US20160177284A1
(en)
|
2014-01-27 |
2016-06-23 |
Molecular Templates, Inc. |
Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
|
|
US20210138076A2
(en)
|
2014-01-27 |
2021-05-13 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
|
ES2749862T3
(es)
*
|
2014-01-27 |
2020-03-24 |
Molecular Templates Inc |
Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
|
|
JP6814634B2
(ja)
|
2014-02-05 |
2021-01-20 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
リボ毒性の一時的な減少に基づき、細胞毒性組換えポリペプチドをスクリーニングし、選択し、同定する方法
|
|
ES2864124T3
(es)
|
2014-03-11 |
2021-10-13 |
Molecular Templates Inc |
Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
|
|
PT3604333T
(pt)
|
2014-03-11 |
2021-06-07 |
Molecular Templates Inc |
Proteínas compreendendo regiões efetoras da subunidade a da toxina shiga próximas de amino-terminais e regiões de ligação do tipo imunoglobulina de direcionamento celular capazes de se ligarem especificamente a cd38
|
|
US11142584B2
(en)
|
2014-03-11 |
2021-10-12 |
Molecular Templates, Inc. |
CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
|
|
CN106103416B
(zh)
|
2014-03-14 |
2021-03-02 |
拉夸里亚创药株式会社 |
作为trpm8拮抗剂的氮杂螺衍生物
|
|
KR102496206B1
(ko)
|
2014-06-11 |
2023-02-06 |
몰레큘러 템플레이츠, 인코퍼레이션. |
프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
|
|
US10550197B2
(en)
|
2014-06-18 |
2020-02-04 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
CAR-expressing NK-92 cells as cell therapeutic agents
|
|
CN105713087B
(zh)
|
2014-11-12 |
2020-05-08 |
北京康乐卫士生物技术股份有限公司 |
人乳头瘤病毒58型单克隆抗体及其应用
|
|
WO2016126950A1
(en)
|
2015-02-05 |
2016-08-11 |
Molecular Templates, Inc. |
Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
|
|
KR102357312B1
(ko)
|
2015-03-04 |
2022-02-03 |
아이쥐엠 바이오사이언스 인코포레이티드 |
Ｃｄ20 결합 분자 및 그의 용도
|
|
CN114656573B
(zh)
*
|
2015-05-30 |
2024-09-27 |
分子模板公司 |
去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
|
|
MX2018001208A
(es)
*
|
2015-07-26 |
2018-03-26 |
Molecular Templates Inc |
Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
|
|
EP3202783A1
(en)
*
|
2016-02-02 |
2017-08-09 |
Ecole Polytechnique Fédérale de Lausanne (EPFL) |
Engineered antigen presenting cells and uses thereof
|
|
CN109195991B
(zh)
|
2016-03-29 |
2023-10-31 |
斯特库比股份有限公司 |
对糖基化pd-l1特异的双重功能抗体及其使用方法
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
JP7011657B2
(ja)
|
2016-10-30 |
2022-02-10 |
シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド |
抗ｐｄ－ｌ１抗体および変異型
|
|
MX2019006656A
(es)
*
|
2016-12-07 |
2019-09-09 |
Molecular Templates Inc |
Polipeptidos efectores de la sub-unidad a de la toxina shiga andamiajes de los efectores de la toxina shiga y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio.
|
|
US11597914B2
(en)
|
2016-12-26 |
2023-03-07 |
Dankook University Cheonan Campus Industry Academic Cooperation Foundation |
IgG type monoclonal antibodies specifically binding to odontoblast surface
|
|
MX2019008348A
(es)
|
2017-01-18 |
2019-10-21 |
Genentech Inc |
Anticuerpos idiotipo contra anticuerpos anti-pd-l1 y usos de estos solicitudes relacionadas.
|
|
KR102590672B1
(ko)
|
2017-01-25 |
2023-10-18 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
JP7201599B2
(ja)
|
2017-02-28 |
2023-01-10 |
中外製薬株式会社 |
プロテインｌを用いたタンパク質精製
|
|
LT3592769T
(lt)
|
2017-03-09 |
2024-08-26 |
Genmab A/S |
Antikūnai, atpažįstantys pd-l1
|
|
EP3601351A1
(en)
|
2017-03-27 |
2020-02-05 |
Celgene Corporation |
Methods and compositions for reduction of immunogenicity
|
|
WO2019059400A1
(ja)
|
2017-09-25 |
2019-03-28 |
Jsr株式会社 |
イムノグロブリン結合タンパク質、及びそれを用いたアフィニティー担体
|
|
US20210017284A1
(en)
|
2018-03-19 |
2021-01-21 |
Abeome Corporation |
High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof
|
|
KR20200143634A
(ko)
|
2018-04-17 |
2020-12-24 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
|
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
|
WO2020154475A1
(en)
|
2019-01-23 |
2020-07-30 |
Molecular Templates, Inc. |
Proteins comprising modified immunoglobulin variable light chains
|